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99 Abstract Diabetic nephropathy is the leading cause of end-stage renal
failure and accounts for 30–40 % of patients entering renal
transplant programmes. The nephroprotective effects of the
neuropeptide pituitary adenylate cyclase-activating polypeptide
(PACAP38) against diabetes have been shown previously, but the
molecular mechanisms responsible for these effects remain
unknown. In the present study, we showed that PACAP treatment
counteracted the diabetes-induced increase in the level of the
proapoptotic pp38MAPK and cleaved caspase-3 and also
decreased the p60 subunit of NFκB. The examined antiapoptotic
factors, including pAkt and pERK1/2, showed a slight increase in
the diabetic kidneys, while PACAP treatment resulted in a notable
elevation of these proteins. PCR and Western blot revealed the
downregulation of fibrotic markers, l ike collagen IV and TGF-β1 in
the kidney. PACAP treatment resulted in increased expression of
the antioxidant glutathione. We conclude that the nephroprotective
effect of PACAP in diabetes is, at least partly, due to its
antiapoptotic, antifibrotic and antioxidative effect in addition to the
previously described antiinflammatory effect.
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14 Abstract Diabetic nephropathy is the leading cause of end-
15 stage renal failure and accounts for 30–40 % of patients enter-
16 ing renal transplant programmes. The nephroprotective effects
17 of the neuropeptide pituitary adenylate cyclase-activating poly-
18 peptide (PACAP38) against diabetes have been shown previ-
19 ously, but the molecular mechanisms responsible for these
20 effects remain unknown. In the present study, we showed that
21 PACAP treatment counteracted the diabetes-induced increase
22 in the level of the proapoptotic pp38MAPK and cleaved
23 caspase-3 and also decreased the p60 subunit of NFκB. The
24 examined antiapoptotic factors, including pAkt and pERK1/2,
25showed a slight increase in the diabetic kidneys, while PACAP
26treatment resulted in a notable elevation of these proteins. PCR
27and Western blot revealed the downregulation of fibrotic
28markers, like collagen IV and TGF-β1 in the kidney. PACAP
29treatment resulted in increased expression of the antioxidant
30glutathione. We conclude that the nephroprotective effect of
31PACAP in diabetes is, at least partly, due to its antiapoptotic,
32antifibrotic and antioxidative effect in addition to the previously
33described antiinflammatory effect.
34Keywords PACAP . Diabetes . Kidney . Oxidative stress .
35Apoptosis
36Introduction
37In the present study, we aimed at investigating the nephro-
38protective mechanisms of the neuropeptide pituitary adenylate
39cyclase-activating polypeptide (PACAP) in an experimental
40diabetic nephropathy. Diabetic nephropathy (DN) is a common
41microvascular complication of diabetes. The development as
42well as the progression of the disease is multifactorial due to its
43profound genetic background besides the well-known environ-
44mental impacts, explaining why 30–40% of all diabetic patients
45suffer from this diabetic complication (Klein et al. 1984).
46Glucose uptake is insulin independent in neuronal, retinal,
47glomerular and endothelial cells, leading to excessive glucose
48uptake in extracellular hyperglycemia (Di Mario and Pugliese
492001). Although a few decades ago diabetic nephropathy was
50considered a primarily glomerular disease, nowadays increasing
51emphasis is put on the tubulointerstitial alterations. Indeed, the
52stage of tubulointerstitial injury is considered to be a reliable
53prognostic factor in progressive kidney diseases, including dia-
54betic nephropathy (Nath 1998). Key factors that are involved in
55diabetic kidney damage are as follows: (1) oxidative stress, (2)
56overproduction of advanced glycation end products (AGE), (3)
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57 apoptosis, (4) excessive production of prosclerotic growth fac-
58 tors and (5) inflammation due to the overproduction of proin-
59 flammatory cytokines (Gnudi 2012; Sun et al. 2013). Since the
60 neuropeptide PACAP is known to exert antiinflammatory,
61 antiapoptotic and antioxidant effects, it seems to be a suitable
62 candidate to prevent the development or delay the progression
63 of DN.
64 PACAP is a member of the vasoactive intestinal polypep-
65 tide (VIP)/secretin/glucagon family and exists in two biolog-
66 ically active forms, PACAP1-27 and PACAP1-38. PACAP38
67 has been shown to have more prolonged effects compared to
68 PACAP27 in most studies (Araki and Takagi 1992; Lindén
69 et al. 1999). PACAP acts via G-protein-coupled receptors:
70 PAC1, specific for PACAP, and VPAC1 and VPAC2 which
71 also bind VIP with the same affinity.
72 In addition to its very first known effect, namely adenylate
73 cyclase activation in the hypophysis, PACAP exerts numerous
74 effects in the endocrine, respiratory, gastrointestinal and uro-
75 genital systems (Miyata et al. 1989; Girard et al. 2012;
76 Koppan et al. 2012; Moody et al. 2012; Nedvig et al. 2012;
77 Syed et al. 2012; Wada et al. 2013). Moreover, the neuropep-
78 tide has been shown to be involved in neuroprotection and
79 general cytoprotection. PACAP is also involved in the regu-
80 lation of carbohydrate metabolism, although its exact role
81 seems to be complex. Its ability to protect β cells and enhance
82 insulin secretion glucose-dependently has been shown in sev-
83 eral studies (Sakurai et al. 2011). Recently, PACAP has been
84 proven to upregulate selenoprotein T in pancreatic β cells,
85 leading to increased insulin secretion (Prevost et al. 2013).
86 However, PACAP also effectively stimulates the release of
87 adrenalin and glucagon. As a result, publications seem to be
88 rather contradictory in the effect of PACAP treatment on
89 blood glucose levels (Sekiguchi et al. 1994; Filipsson et al.
90 1998; Yada et al. 2000).
91 PACAP exerts renoprotective effects against several neph-
92 rotoxic agents, like hydrogen peroxide-induced oxidative
93 stress in vitro and in vivo or ischemia/reperfusion injury
94 (Szakaly et al. 2008; Horvath et al. 2011; Khan et al. 2012;
95 Reglodi et al. 2012). PACAP has also been shown to attenuate
96 kidney injuries induced by multiple myeloma, cyclosporine
97 A, gentamicin and short-term diabetes (Arimura et al. 2006; Li
98 et al. 2007, 2008). Recently, we have provided evidence for
99 similar protection against 8-week diabetes-induced kidney
100 damage (Banki et al. 2013).
101 The protective effects of PACAP are mediated through its
102 antiinflammatory, antiapoptotic and antioxidative effects. The
103 antiinflammatory effects involve the inhibition of proinflam-
104 matory cytokine (i.e. tumor necrosis factor α (TNFα) and
105 interleukin-6 (IL-6) production and NFκB activation through
106 PAC1- and VPAC1 receptor-mediated signaling (Arimura
107 et al. 2006). We have already proven the importance of the
108 antiinflammatory effect in long-term diabetic nephropathy,
109 resulting in marked downregulation of several cytokines, like
110cytokine-induced neutrophil chemokine (CINC-1), tissue in-
111hibitor of metalloproteinase 1 (TIMP-1), lipopolysaccharide-
112induced CXC chemokine (LIX) and monokine induced by
113gamma interferon (MIG) (Banki et al. 2013). However,
114the further mechanisms leading to the significant
115nephroprotective effect in diabetic nephropathy remain
116unknown.
117Materials and Methods
118Animals
119Adult male Wistar rats (n=33) weighing 250–300 g were
120housed under light/dark cycles of 12:12 h and received normal
121rat chow and drinking water ad libitum. Rats were randomly
122divided into four groups: (1) untreated control (n=10); (2)
123PACAP-treated control (n=6); (3) untreated diabetic (n=7);
124and (4) PACAP-treated diabetic (n=10). Control animals re-
125ceived saline i.v., while diabetic groups were administered
12665 mg/kg streptozotocin (Sigma, Hungary) i.v. PACAP-
127treated animals were given 20 μg PACAP1-38 i.p. every
128second day, starting simultaneously with the streptozotocin
129injection.
130Animals were considered diabetic in cases where they
131showed elevated blood glucose levels (>11 mmol/l) measured
132by a blood glucose monitor (Accu-Check Active, Roche,
133Hungary). After 8 weeks of survival, animals were sacrificed
134with an overdose of anaesthetics and the kidneys were re-
135moved. For RT-PCR and Western blot, kidney samples
136were taken from the cortex of the kidney close to the superior
137pole. Experimental procedures were carried out in accordance
138with approved protocols (University of Pécs; BA02/2000-
13915024/2011).
140RT-PCR Analysis
141Tissue samples were dissolved in Trizol (Applied Biosystems,
142Foster City, CA, USA) for 30 min and mechanically homog-
143enized. After the addition of 20 % RNase-free chloroform,
144samples were centrifuged at 4 °C at 10,000×g for 15 min.
145Samples were incubated in 500 μL of RNase-free isopropanol
146at −20 °C for 1 h and then total RNAwas harvested in RNase-
147free water and stored at −20 °C. The assay mixture for reverse
148transcriptase reaction contained 2 μg RNA, 0.112 μM
149oligo(dT), 0.5 mM dNTP, 200 U of High Capacity RT
150(Applied Bio-Systems) in 1× RT buffer. Primers used in the
151RT-PCR analysis of collagen IV all isotype were as follows:
152Col4a1: 5′-TCG GCT ATT CCT TCG TGA TG-3′ and 5′-
153GGA TGG CGT GGG CTT CTT-3′ (GenBank ID:
154NM_009931.2, 52 °C, amplimer size 209 bp); and for ac-
155tin—Actb: 5′-GCC AAC CGT GAA AAG ATG A-3′ and 5′-
156CAA GAA GGA AGG CTG GAA AA-3′ (GenBank ID:
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157 NM_007393, amplimer size 462 bp). Amplifications were
158 performed in a thermal cycler (Labnet MultiGene™ 96-well
159 Gradient Thermal Cycler; Labnet International, Edison, NJ,
160 USA) in a final volume of 25 μL (containing 1 μL forward
161 and reverse primers [0.4 μM], 0.5 μL dNTP [200 μM] and 5
162 U of Promega GoTaq® DNA polymerase in 1× reaction
163 buffer) as follows: 95 °C, 2 min, followed by 35 cycles
164 (denaturation, 94 °C, 1 min; annealing at 52 °C for Col4a1
165 or 53 °C for Actb for 1 min; extension, 72 °C, 90 s) and then
166 72 °C, 10 min. PCR products were analysed by electrophore-
167 sis in 1.2 % agarose gel containing ethidium bromide. Actin
168 was used as the internal control. Optical density of signals was
169 measured by using ImageJ 1.40 g freeware and results were
170 normalised to actin.
171 Western Blot
172 The specimens were put into 100 μL of ice-cold homogeni-
173 zation buffer containing 50 mM Tris–HCl buffer (pH 7.0),
174 10 μg/mL Gordox, 10 μg/mL leupeptine, 1 mM
175 phenylmethylsulphonyl-fluoride (PMSF), 5 mM benzamidine
176 and 10μg/mL trypsin inhibitor as protease inhibitors. Samples
177 were stored at −70 °C. Tissue samples were sonicated by
178 pulsing burst for 30 s at 40 A (Cole-Parmer, IL, USA).
179 Samples for SDS-PAGE were prepared by the addition of
180 fivefold concentrated electrophoresis sample buffer (20 mM
181 Tris–HCl pH 7.4, 0.01% bromophenol blue dissolved in 10%
182 SDS, 100 mM β-mercaptoethanol) to kidney homogenates to
183 set equal protein concentration of samples and boiled for
184 10 min. About 40 μg of protein was separated by 7.5 %
185 SDS-PAGE gel for detection of tAkt, pAkt, pERK1/2,
186 p38MAPK, pp38MAPK, cleaved caspase-3, TGF-β1, colla-
187 gen type IV, β-actin and NFκB. Proteins were transferred
188 electrophoretically to nitrocellulose membranes. After
189 blocking with 5 % non-fat dry milk in phosphate-buffered
190 saline with 0.1 % Tween 20 (PBST), membranes were washed
191 and exposed to the following primary antibodies overnight at
192 4 °C: monoclonal anti-Akt, monoclonal phospho-specific
193 anti-Akt-1 Ser473, monoclonal phospho-specific anti-ERK1/
194 2 Thr202/Tyr204, monoclonal anti-p38 MAPK, monoclonal
195 phospho-specific anti-p38 MAPK (1:500; Cell Signaling
196 Technology, USA), monoclonal anti-NFκB, monoclonal
197 anti-caspase-3 (1:500; Santa Cruz, USA), polyclonal anti-
198 TGF-β1 antibody (1:400; Abcam, Cambridge, UK), mono-
199 clonal anti-collagen type IV antibody (1:400; Chemicon/
200 Millipore, USA) and monoclonal anti-actin antibody
201 (1:10,000; Sigma, Hungary) were used. After washing for
202 40 min in PBST, membranes were incubated with anti-
203 mouse IgG (1:1500; Bio-Rad Laboratories, USA) or anti-
204 rabbit IgG (1:3,000; Bio-Rad Laboratories, USA). Signals
205 were detected by enhanced chemiluminescence (Millipore,
206 USA) according to the instructions of the manufacturer.
207 Actin was used as the internal control. Optical density of
208Western blot signals was measured by using ImageJ 1.40 g
209freeware and the results were normalised to actin.
210Biochemical Assay of Oxidative Stress Markers
211Malondialdehyde (MDA) was measured as previously de-
212scribed (Placer et al. 1966). Briefly, MDA was measured in
213kidney homogenates with the addition of TBA (saturated
214thiobarbituric acid in 10 % perchloric acid)-TCA (20 % tri-
215chloroacetic acid) reagent. After incubation at 100 °C for
21620 min, samples were placed in ice-cold water and were
217centrifuged for 15 min at 4,000 rpm. MDA concentration
218was determined spectrophotometrically by measuring the ab-
219sorbance at 532 nm against TBA+TCA reagent. From the
220concentration vs. extinction curve, the MDA value of the
221tissue sample could be calculated in micromole per gram
222tissue weight.
223Reduced glutathione (GSH) was quantified as described by
224Sedlak and Lindsay (1968). After adding 10 % TCA, kidney
225homogenates were centrifuged for 15min at 4,000 rpm. TRIS-
226buffer was added to the supernatant and samples were mea-
227sured at 412 nm after adding DTNB to the mixture. Values of
228glutathione were expressed in micromole per gram tissue
229weight.
230Kidney homogenates were centrifuged for 20 min at
23116,000 rpm, and the supernatant was used to measure the
232concentration of superoxide dismutase (SOD) as described
233previously (Misra and Firdovich 1972). SOD inhibited the
234transformation of adrenaline to adrenochrome, which
235absorbed maximally at 480 nm. Quantification of SOD is
236based on the degree of inhibition. The value of SOD was
237given in international units per gram tissue weight.
238Electron Microscopy
239Kidney samples were cut into maximum 1 mm3 pieces and
240were fixed in 5 % glutaraldehyde. Post-fixation was per-
241formed with 1 % osmium tetroxide. After dehydration in
242ascending alcohol and subsequent transfer to propylene oxide,
243samples were embedded in Araldite resin. Semithin sections
244were cut by a ultramicrotome (Leica Ultracut R) and stained
245by toluidine blue. Ultrathin sections were prepared from the
246area of interest and were contrasted by uranyl-acetic acid and
247lead citrate. Slides were eventually examined using JEOL
2481200 EX-II electron microscope.
249Statistical Analysis
250Statistical analysis was performed by Microsoft Office Excel
251and GraphPad software. Analysis of variance (ANOVA) with
252Bonferroni correction was used to detect significant differ-
253ences between groups. p value less than 0.05 was considered
254to be statistically significant.
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255 Results
256 RT-PCR analysis revealed marked elevation in the collagen IV
257 mRNA, a collagen uniquely present in the basement mem-
258 brane. PACAP treatment successfully counteracted this in-
259 crease (Fig. 1). We then measured the protein expression of
260 two key factors involved in the fibrotic processes of diabetic
261 nephropathy, namely collagen IVand TGF-β1. Diabetes result-
262 ed in excessive expression of collagen IV and TGF-β1, which
263 was attenuated by PACAP38, reaching the level of normal
264 kidneys in the case of collagen IV (Figs. 2 and 3a, b).
265 Next we investigated the levels of anti- and proapoptotic
266 proteins by Western blot. PACAP alone caused increased
267 expression of the phosphorylated form of Akt. Diabetic ne-
268 phropathy is accompanied by excessive apoptosis, shown by
269 the upregulation of the phosphorylated forms of the
270 proapoptotic pp38MAPK. However, the antiapoptotic Akt
271 and ERK1/2 were also activated. PACAP treatment in diabetic
272 animals led to a remarkable increase in the activation of the
273 antiapoptotic factors, like pAkt and pERK1/2, and decreased
274 the level of pp38MAPK. PACAP treatment was effective in
275 decreasing the elevated cleaved caspase-3 levels observed in
276 diabetic animals. We then aimed at measuring the level of p60
277 NFκB, a protein known to control both cytokine production
278 and cell survival. We found that p60 NFκBwas upregulated in
279 the diabetic samples. PACAP treatment in diabetic kidneys
280 resulted in a remarkable decrease in the p60 subunit of NFκB
281 (Figs. 2 and 3c–h).
282 Biochemical assay of the oxidative stress markers revealed
283 a significant elevation in the kidney GSH concentration of the
284 PACAP-treated diabetic group compared to the untreated
285 diabetic one. No changes were observed in the kidney SOD
286 orMDA concentration of the diabetic groups compared to that
287 of the intact animals; however, PACAP caused a significant
288 increase in the SOD level of the control animals (Fig. 4).
289 Electron microscopy revealed segmental thickening of the
290 glomerular basement membrane (GBM) in several parts of the
291 untreated diabetic glomeruli. The thickness of these parts of
292 the GBM was significantly greater than the GBM in control,
293PACAP-treated control and PACAP-treated diabetic kidneys.
294However, we could not detect any changes between the non-
295thickened part of the GBM in diabetic animals and the thick-
296ness of the GBM in the control. Most importantly, PACAP-
297treated diabetic animals did not show this focal segmental
298thickening; there was no difference between PACAP-treated
299or untreated control and PACAP-treated diabetic animals.
300Podocytes in the PACAP-treated diabetic kidneys did not
301show any morphological alterations compared to the control
302groups, although severe podocyte injury was present in the
303diabetic glomeruli with marked foot process broadening and
304extensive flattening (Fig. 5).
305Discussion
306In the present study, we demonstrated that in vivo PACAP
307treatment exhibits protective effect through inhibiting apopto-
308tic, fibrotic and oxidative pathways, key mediators in the
309development and progression of diabetic nephropathy and
310preventing diabetes-induced podocyte injury in 8-week dia-
311betes. The present experiment was based on our previous
312finding, showing that PACAP38 effectively counteracted the
Q2 Fig. 1 mRNA expression pattern of collagen type IV in control, PACAP-
treated control, diabetic and PACAP-treated diabetic kidneys. For RT-
PCR reactions, actin was used as the control. ***p<0.001 vs. control;
###p<0.001 vs. control + PACAP; &&&p<0.001 vs. diabetes
Fig. 2 Western blots of collagen type IV, TGF-β1, pERK1/2, pAkt,
pp38MAPK, cleaved caspase-3 and p60 NFκB in untreated or PACAP-
treated control and diabetic animal groups. For Western blot analysis, β-
actin was used as a control
J Mol Neurosci
JrnlID 12031_ArtID 249_Proof# 1 - 29/01/2014
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
313 histological alterations of 8-week diabetic nephropathy.
314 Decreased PAS-positive area expansion, glycogen deposits
315 in tubular epithelial cells and significantly diminished vascu-
316 lar hyalinosis proved the ameliorative effect of PACAP.
317 Moreover, we provided evidence that this effect is at least
318 partially mediated through its antiinflammatory effect (Banki
319 et al. 2013).
320 As we mentioned earlier, the effect of exogenous PACAP
321 on glucose homeostasis is not fully elucidated. However, the
322 pivotal role of endogenous PACAP on regulating blood sugar
323 level seems to be more evident. Chronic administration of the
324 antagonist PACAP6-27 was found to deteriorate insulin sen-
325 sitivity and glucose tolerance in mice (Q3 Green et al. 2006).
326 Newborn PACAP knockout mice showed decreased glucose
327 and intrahepatic glucagon levels, but significantly higher
328insulin levels compared to the control PACAP+/+ mice (Gray
329et al. 2001). Although PACAP protects pancreatic β cells
330against streptozotocin-induced apoptosis, under our experi-
331mental circumstances, we could not find significant changes
332between the blood sugar levels of the PACAP-treated and
333untreated diabetic rats after 8 weeks of survival, meaning that
334this factor cannot be responsible for the ameliorative effect in
335diabetic nephropathy (Onoue et al. 2008; Banki et al. 2013).
336In the present study, we found that diabetes resulted in
337upregulated NFκB levels compared to the controls, while
338PACAP treatment effectively diminished the renal NFκB ex-
339pression. Several previous studies revealed that PACAP, which
340is structurally similar to the related VIP peptide, prevents NFκB
341translocation to the nucleus via inhibition of IκB phosphoryla-
342tion both in vitro and in vivo (Leceta et al. 2000; Delgado and
Fig. 3 Effect of 8-week PACAP treatment and diabetes on the protein
expression of collagen type IV (a), TGF-β1 (b), pERK1 (c), pERK2 (d),
pAkt (e), pp38MAPK (f), cleaved caspase-3 (g) and p60 NFκB (h).
*p<0.05; **p<0.01; ***p<0.001 vs. control; #p<0.05; ###p<0.01;
###p<0.001 vs. control+PACAP; &p<0.05; &&p<0.01; &&&p<0.001
vs. diabetes
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343 Ganea 2001; Delgado et al. 2002; Ganea and Delgado 2003).
344 Antioxidants and inhibitors of the renin-angiotensin-
345 aldosterone system, which exert their nephroprotective effect
346 partially through controlling the action of NFκB, are extensive-
347 ly used in the treatment of diabetic nephropathy (Liu et al.
348 2009). In diabetic nephropathy, NFκB can be activated by
349 mesangial cells, hyperglycemia-induced ROS production,
350 renin-angiotensin-aldosterone system (RAAS) activation,
351 TGF-β1, TNFα and interleukins (Iwamoto et al. 2005; Gnudi
352 2012). NFκB plays an important role in several renal diseases,
353 such as nephritis, proteinura and tubulointerstitial disorders,
354 and it is the key transcriptional regulator of diabetic kidney
355 disease (Sakurai et al. 1996; Iwamoto et al. 2005). It activates
356 the transcription of a variety of factors involved in cell prolif-
357 eration and inflammation contributing to the progression of
358 diabetic nephropathy (Navarro-González et al. 2011).
359Mesangial cell proliferation, tubular cell damage and excessive
360secretion of proinflammatory cytokines, chemokines and adhe-
361sion molecules occur as a result of NFκB activation (Mezzano
362et al. 2004; Chen et al. 2008).
363Activation of NFκB under diabetic conditions is assumed
364to mediate ROS-induced apoptotic changes (Aoki et al. 2011).
365Extracellular signal-regulated kinase (ERK) 1/2, p38 mitogen
366activated protein kinase (MAPK) and Jun kinase-mediated
367pathways are stimulated upon NFκB activation. In this study,
368we showed that PACAP increased the expression of
369antiapoptotic factors, like pAkt and pERK1/2, while down-
370regulated the proapoptotic pp38MAPK. The markedly in-
371creased expression of the antiapoptotic proteins in untreated
372diabetic animals may result from the induction of the protec-
373tive compensatory mechanisms. The antiapoptotic effect of
374PACAP was associated with decreased cleaved caspase-3.
375Caspase-3, as an effector caspase, plays a critical role in
376receptor-mediated, mitochondria-dependent and endoplasmic
377reticulum stress-induced apoptotic mechanisms, which are
378involved in hyperglycemia-induced podocyte loss (Susztak
379et al. 2006; Tunçdemir and Oztürk 2011; Gui et al. 2012).
380Apoptosis is a rare event in the normal kidney; however, it is
381present in human diabetic kidney biopsies, similar to other
382kidney disorders. Not only proximal and distal tubular cells
383but also endothelial and mesangial cells are affected by apo-
384ptosis in diabetes (Woo 1995; Kumar et al. 2004).
385Similar to the pathomechanism of the tubulointerstitial injury
386in myeloma kidney, tubular epithelial cells start to produce
387excessive amount of proinflammatory cytokines in diabetic
388nephropathy as well. TGF-β1 is a prosclerotic cytokine pro-
389duced by mesangial and proximal tubular cells (Gilbert et al.
3901998). It is the key mediator of hyperglycemia-induced changes
391in the kidney, accelerating the production of extracellular matrix
392in excess through epithelial-to-mesenchymal cell transformation
393(di Paolo et al. 1996; Hills Paul and Squires 2010). The accu-
394mulation of fibronectin, collagen IV and laminin is caused by
395simultaneous overproduction and decreased breakdown of pro-
396teins in mesangial matrix, glomerular and tubular basal mem-
397brane and interstitium, resulting in a severely damaged renal
398morphology and function (Mauer et al. 1984; Steffes et al.
3991989). Similar to our results in rat kidney, PACAP was found
400to significantly lower the TGF-β1 production in stimulated
401macrophages (Sun et al. 2000). Li et al. reported that PACAP
402provided a protective effect against early diabetic nephropathy.
403They found that this effect is mediated via inhibiting TGF-β1
404and TNFα pathways, resulting in remarkably attenuated histo-
405logical changes in the PACAP-treated animals. Similar to Li
406et al., in the present study, we showed decreased TGF-β1 and
407collagen IV levels in the PACAP-treated diabetic compared to
408the untreated diabetic kidneys (Li et al. 2008). Therefore, these
409findings provide explanation for the suppressed extracellular
410matrix expansion observed in the histological sections of
411PACAP-treated animals. Antioxidants and AGE inhibitors,
Fig. 4 Changes in renal expression of glutathione (GSH; a), superoxide
dismutase (SOD; b) and malondialdehyde (MDA; c). Values are given as
mean micromoles per gram, international units per gram and micromoles
per gram ± SEM, respectively. *p<0.05 vs. diabetes + PACAP; #p<0.05
vs. control
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412 which are already commonly used in clinical practice, also
413 effectively reduce TGF-β1, fibronectin and collagen IV levels
414 (Ha et al. 1999; Kelly et al. 2001). The results of anti-TGF-β1
415 treatments are promising; therefore, any candidate, which
416 downregulates the TGF-β1 pathway, could be effective in the
417 treatment of diabetic nephropathy (Sharma et al. 1996; Ziyadeh
418 et al. 2000).
419 The importance of oxidative stress in the development of
420 diabetes and diabetic complications is well known (Usuki et al.
421 2011). The diabetogenic effect of streptozotocin in pancreaticβ
422 cells also involves the overproduction of nitric oxide (NO) and
423 superoxide (O2
–) (Nukatsuka et al. 1988; Kaneto et al. 1995).
424 The mitochondrial free radicals were shown to stimulate the
425 polyol-PKC, hexosamine and AGE pathways, contributing to
426 the progression of DN. The vital role of glutathione is based on
427 its ability to neutralize electrophils produced by metabolic
428 processes or external stimuli in order to prevent the organism
429 against their harmful effects. Conditions associated with high
430 levels of free radicals, like diabetes, probably inactivate the
431 mitochondrial GSH carriers, resulting in depressed antioxidant
432 mechanisms. Non-enzymatic glycation of renal mitochondrial
433 proteins was shown to be at least partially responsible for these
434changes (Lash 2006). Moreover, increased activity of NADPH
435oxidase results in severely lowered NADPH levels, leading to
436impaired glutathione recovery. Therefore, not only the in-
437creased oxidative stress but also the inactivated defence mech-
438anisms contribute to the oxidative damage of the renal cells,
439leading to more severe consequences of the oxidative agents
440(Stanton 2011; Gnudi 2012). Changes in the concentration and
441redox status of GSH lead to mitochondrial DNA damage and
442induction of apoptotic pathways (Marchetti et al. 1997; Davis
443et al. 2001). We found that PACAP is capable of normalising
444the decreased GSH levels in the diabetic kidney, suggesting an
445antioxidative effect of PACAP. This finding is similar to our
446previous studies, where PACAP was found to exert antioxida-
447tive effects in oxidative stress-induced renal and hepatic cell
448damage, intestinal cold preservation and warm ischemic injury
449(Ferencz et al. 2010a, 2010b; Horvath et al. 2011). Usually
450diabetes is also associated with decreased superoxide dismutase
451(SOD) and elevated malondialdehyde (MDA) levels; however,
452under our experimental circumstances, we could not detect
453diabetes-induced changes in these factors.
454Based on these data, PACAP seems to be a promising
455candidate in treating diabetic nephropathy. Similar to other
Fig. 5 Representative electron microscopic images of diabetic (a) and
PACAP-treated diabetic kidneys (b). Focal segmental thickening of the
glomerular basement membrane (GBM) (paired arrows) was observed in
the diabetic kidney, while other parts of the GBM remained unchanged
(paired arrowheads). Fusion of the foot processes of the podocytes
(encircled) was also remarkable. PACAP treatment effectively counteracted
the diabetes-induced GBM thickening and podocyte injury (b). Scale bar=
2μm. Inserts show enlarged encircled parts of pictures a and b to visualize
the severe injury of the podocyte foot processes (fused foot processes
marked by asterisks, c), while PACAP treatment resulted in intact podocyte
foot processes (foot processes marked by asterisks, d). Thickness of GBM
(e). Basement membrane thickness measurements were performed in the
entire basement membrane in control, control + PACAP and in diabetes +
PACAP-treated groups. Data are given separately for segmental thicken-
ings in diabetic animals (bar: diabetes segmental) and for areas showing no
segmental thickening (bar: diabetes nonsegmental). Data show mean ±
SEM. ***p<0.001 vs. all other groups
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456 studies showing that PACAP is a strong cytoprotective agent,
457 we have also provided evidence that PACAP is highly effective
458 in diabetic nephropathy. This efficacy is most probably due to
459 PACAP acting at several levels and directly and/or indirectly
460 (via antiinflammatory, antiapoptotic and antioxidant mecha-
461 nisms) affectingmore cell types in the kidney. However, several
462 aspects have to be examined before the clinical application of
463 PACAP. In rats, no side effects were observed after systemic
464 administration of PACAP. Indeed, even a human study proved
465 that systemic infusion of the peptide causes no changes in the
466 physiological parameters apart from transient flushing (Li et al.
467 2007). The other drawback of systemic PACAP administration
468 is the poor bioavailability, since the half life of the peptide in the
469 circulation is only 5–10 min due to its rapid degradation by
470 dipeptidyl peptidase IV (DPPIV) (Banks et al. 1993;
471 Bourgault et al. 2008). However, nowadays, several studies
472 aim at finding an easy and reliable way of PACAP treatment
473 (Onoue et al. 2011).
474 In summary, our present study demonstrated the molecular
475 mechanisms involved in the protective effect of PACAP.
476 Besides the contribution of the previously proven
477 antiinflammatory effect, antiapoptotic, antioxidative and
478 antifibrotic mechanisms are responsible for the protective
479 effect of PACAP in 8-week diabetic nephropathy in rats.
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